• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term outcomes of genome-edited "universal" CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center.

作者信息

Guardo Daniela, Mishra Avijeet Kumar, Rashed Hebatalla, Gilmour Kimberly, Adams Stuart, Pinner Danielle, Sauer Martin, Vora Ajay, Veys Paul, Pavasovic Vesna, Rao Kanchan, Qasim Waseem

机构信息

Department of Bone Marrow Transplant, Great Ormond Street Hospital for Children National Health Service Trust & University College London Institute of Child Health, London, United Kingdom.

Department of Bone Marrow Transplant and Cell Therapy, Hannover Medical School, Hannover, Germany.

出版信息

Blood Adv. 2025 Sep 23;9(18):4750-4754. doi: 10.1182/bloodadvances.2025016366.

DOI:10.1182/bloodadvances.2025016366
PMID:40601899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12496233/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d215/12496233/935491391d06/BLOODA_ADV-2025-016366-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d215/12496233/626c6c499dbc/BLOODA_ADV-2025-016366-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d215/12496233/935491391d06/BLOODA_ADV-2025-016366-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d215/12496233/626c6c499dbc/BLOODA_ADV-2025-016366-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d215/12496233/935491391d06/BLOODA_ADV-2025-016366-gr1.jpg

相似文献

1
Long-term outcomes of genome-edited "universal" CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center.单个儿科中心基因组编辑的“通用”CAR19 T细胞治疗复发/难治性B淋巴细胞白血病的长期结果
Blood Adv. 2025 Sep 23;9(18):4750-4754. doi: 10.1182/bloodadvances.2025016366.
2
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.CD22 导向的 CAR T 细胞疗法治疗 CD19 导向的 CAR T 细胞疗法后进展的大 B 细胞淋巴瘤：一项剂量探索性 1 期研究。
Lancet. 2024 Jul 27;404(10450):353-363. doi: 10.1016/S0140-6736(24)00746-3. Epub 2024 Jul 9.
3
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.替雷利珠单抗自体白细胞介素用于复发或难治性B细胞恶性肿瘤：一项开放标签、多中心、1/2期研究的结果
Lancet Haematol. 2025 Apr;12(4):e282-e293. doi: 10.1016/S2352-3026(24)00377-6. Epub 2025 Mar 13.
4
Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.循环肿瘤 DNA 的动态监测揭示了接受 CAR T 细胞治疗的复发或难治性大 B 细胞淋巴瘤患者的结局和基因组改变。
J Immunother Cancer. 2024 Mar 4;12(3):e008450. doi: 10.1136/jitc-2023-008450.
5
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
6
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.异基因CD5特异性嵌合抗原受体T细胞疗法治疗复发/难治性T细胞急性淋巴细胞白血病：一项1期试验。
Nat Med. 2025 Jan;31(1):126-136. doi: 10.1038/s41591-024-03282-2. Epub 2024 Oct 1.
7
Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Español de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee.嵌合抗原受体T细胞（CAR-T）疗法时代小儿急性淋巴细胞白血病的移植后复发。西班牙血液移植与细胞治疗协作组（GETH-TC）儿科委员会的多中心分析
Cytotherapy. 2025 Apr;27(4):438-445. doi: 10.1016/j.jcyt.2024.11.016. Epub 2024 Dec 2.
8
Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study.复发/难治性B细胞非霍奇金淋巴瘤异基因造血干细胞移植后的长期结局：一项意大利多中心协作研究
Transplant Cell Ther. 2025 Jun 18. doi: 10.1016/j.jtct.2025.06.004.
9
Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.Blinatumomab 治疗与儿童 B 细胞急性淋巴细胞白血病患者异基因造血细胞移植后的良好结局相关。
Transplant Cell Ther. 2024 Feb;30(2):217-227. doi: 10.1016/j.jtct.2023.10.024. Epub 2023 Nov 4.
10
CAR19-T/NK cell and circular aptamer-drug conjugate (ApDC) combination treatment increases immunotherapy efficacy.CAR19-T/NK细胞与环状适体-药物偶联物（ApDC）联合治疗可提高免疫治疗效果。
Mol Cell Biochem. 2025 Jul 13. doi: 10.1007/s11010-025-05347-3.

引用本文的文献

1
Gene-edited CAR T cells: going the distance in B-ALL.
Blood Adv. 2025 Sep 23;9(18):4755-4756. doi: 10.1182/bloodadvances.2025017508.

本文引用的文献

1
Base edited "universal" donor CAR T-cell strategies for acute myeloid leukaemia.用于急性髓系白血病的碱基编辑“通用”供体嵌合抗原受体T细胞策略
Leukemia. 2025 Oct 1. doi: 10.1038/s41375-025-02720-5.
2
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.博纳吐单抗用于儿童标准风险B细胞急性淋巴细胞白血病的治疗
N Engl J Med. 2025 Feb 27;392(9):875-891. doi: 10.1056/NEJMoa2411680. Epub 2024 Dec 7.
3
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.Blinatumomab 治疗成人 MRD 阴性急性淋巴细胞白血病。
N Engl J Med. 2024 Jul 25;391(4):320-333. doi: 10.1056/NEJMoa2312948.
4
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.CD70 靶向的同种异体嵌合抗原受体 T 细胞疗法治疗晚期透明细胞肾细胞癌。
Cancer Discov. 2024 Jul 1;14(7):1176-1189. doi: 10.1158/2159-8290.CD-24-0102.
5
FDA Adds Boxed Warning to CAR T-Cell Therapies, but Says Benefits Outweigh Risks of Secondary Cancers.美国食品药品监督管理局（FDA）给嵌合抗原受体T细胞（CAR T）疗法添加了黑框警告，但表示其益处大于引发继发性癌症的风险。
JAMA. 2024 Mar 12;331(10):818-820. doi: 10.1001/jama.2024.1011.
6
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.嵌合抗原受体T细胞（CAR-T）疗法后出现继发性恶性肿瘤报告后的未解问题。
Nat Med. 2024 Feb;30(2):338-341. doi: 10.1038/s41591-023-02767-w.
7
Genome Editing in Engineered T Cells for Cancer Immunotherapy.基因编辑工程化 T 细胞用于癌症免疫治疗。
Hum Gene Ther. 2023 Sep;34(17-18):853-869. doi: 10.1089/hum.2023.128.
8
Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia.经碱基编辑的 CAR7 T 细胞治疗复发型 T 细胞急性淋巴细胞白血病。
N Engl J Med. 2023 Sep 7;389(10):899-910. doi: 10.1056/NEJMoa2300709. Epub 2023 Jun 14.
9
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.复发/难治性多发性骨髓瘤中同种异体靶向BCMA的CAR T细胞：1期UNIVERSAL试验中期结果
Nat Med. 2023 Feb;29(2):422-429. doi: 10.1038/s41591-022-02182-7. Epub 2023 Jan 23.
10
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.ELIANA 试验中复发/难治性急性淋巴细胞白血病的儿科和年轻成年患者接受 tisagenlecleucel 治疗的 3 年更新结果。
J Clin Oncol. 2023 Mar 20;41(9):1664-1669. doi: 10.1200/JCO.22.00642. Epub 2022 Nov 18.